OR WAIT null SECS
December 06, 2019
The expansion will enhance the company’s specialty drug product capabilities.
The new software lets users choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
Cambrex reports that the acquisition by the investment group will facilitate ongoing growth.
December 05, 2019
Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.
BioMed X has announced the successful completion of its first joint research project in the fields of COPD and IPF that it had undertaken with Boehringer Ingelheim.
Iontas has entered into a collaboration agreement with Adaptate Biotherapeutics for the generation and optimization of antibodies for novel immune-oncology targets.
GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau have signed an agreement to jointly establish a training center for biopharmaceutical professionals.
The new 50,000-square-foot facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.
November 25, 2019
Through the program, the company will introduce seven new manufacturing sites that will be completed and operational by the end of 2020.
The companies announced a commercial supply agreement following FDA’s accelerated approval.